Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 22300840)

1.

The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.

Donegan KL, Walker AS, Dunn D, Judd A, Pillay D, Menson E, Lyall H, Tudor-Williams G, Gibb DM; Collaborative HIV Paediatric Study; UK HIV Drug Resistance Database.

Antivir Ther. 2012;17(4):599-603. doi: 10.3851/IMP2015. Epub 2011 Dec 15. Erratum in: Antivir Ther. 2012;17(4):769.

PMID:
22300840
2.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
3.

Resistance profile of darunavir: combined 24-week results from the POWER trials.

de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, Picchio G, Lefebvre E, de Béthune MP.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):379-88. doi: 10.1089/aid.2007.0173.

PMID:
18327986
4.

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

Sension M, Cahn P, Domingo P, Hodder S, Opsomer M, Lathouwers E, Van de Casteele T, Tomaka F.

HIV Med. 2013 Aug;14(7):437-44. doi: 10.1111/hiv.12024. Epub 2013 Mar 10.

PMID:
23480640
5.

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.

Antivir Ther. 2011;16(1):99-108. doi: 10.3851/IMP1719.

PMID:
21311113
6.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
7.

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.

Lathouwers E, De La Rosa G, Van de Casteele T, Baeten B, Tomaka F, De Meyer S, Picchio G.

Antivir Ther. 2013;18(3):289-300. doi: 10.3851/IMP2569. Epub 2013 Apr 4.

PMID:
23558157
8.

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Phillips A, Mackie N, Pozniak A, Dunn D.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19739. doi: 10.7448/IAS.17.4.19739. eCollection 2014.

9.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
10.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
11.

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulié C, Wirden M, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Feb;52(2):491-6. Epub 2007 Nov 26.

12.
13.

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group.

Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799.

PMID:
21685536
14.

Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

Delaugerre C, Buyck JF, Peytavin G, Viard JP, Chaix ML, Zucman D, Mortier E, Blanche S, Rouveix E, Force G, Aegerter P, de Truchis P.

J Clin Virol. 2010 Mar;47(3):248-52. doi: 10.1016/j.jcv.2009.12.022. Epub 2010 Jan 22.

PMID:
20097121
15.

Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.

Hill A, Marcelin AG, Calvez V.

HIV Med. 2009 Nov;10(10):620-6. doi: 10.1111/j.1468-1293.2009.00734.x. Epub 2009 Jul 6.

PMID:
19601995
16.

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.

Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C.

Antivir Ther. 2011;16(1):59-65. doi: 10.3851/IMP1710.

PMID:
21311109
17.

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.

AIDS. 2009 Sep 10;23(14):1829-40. doi: 10.1097/QAD.0b013e32832cbcec.

PMID:
19474650
18.

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F.

HIV Med. 2013 Jan;14(1):49-59. doi: 10.1111/j.1468-1293.2012.01060.x. Epub 2012 Oct 23.

PMID:
23088336
19.

Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2012 Apr;67(4):995-1000. doi: 10.1093/jac/dkr569. Epub 2012 Jan 17.

20.

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.

Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, Workman C, Van De Casteele T, De Doncker P, Lathouwers E, Tomaka F.

AIDS. 2011 Apr 24;25(7):929-39. doi: 10.1097/QAD.0b013e328345ee95.

PMID:
21346512
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk